Naveed Sattar is internationally recognised in cardiometabolic disease, with epidemiology, mechanistic and trial expertise. He has contributed to several randomised lifestyle trials (e.g. DIRECT, STANDBY, UPBEAT, EUROFIT, RE-DIRECT) and multiple drug trials (e.g. REMOVAL, TRUST, AMPLITUDE-O, EMPEROR-HF) and has ongoing activity in several large cardiovascular outcome trials, with increasing focus on weight lowering interventions. He has served on guideline committees, including ESC 2023 Guidelines on diabetes and cardiovascular diseases; Joint British Societies 3 CVD prevention recommendations; SIGN obesity and CVD prevention guidelines (as Chair). He has over 1600 published papers, with more than 185K citations, working collaboratively with hundreds of colleagues nationally and internationally. Naveed has received several national and international awards, is an Associate Editor for Diabetes Care, and past Associate Editor for Circulation and Diabetologia. He contributes to new health initiatives in the Scottish Health Service and in 2023 was appointed UK Government’s Obesity Healthcare Goals Programme Chair.